Skip to main content
Top
Published in: Endocrine 2/2014

01-06-2014 | Original Article

Glycemic variability in normal glucose regulation subjects with elevated 1-h postload plasma glucose levels

Authors: Jian-bin Su, Tong Chen, Feng Xu, Xue-qin Wang, Jin-feng Chen, Gang Wu, Yan Jin, Xiao-hua Wang

Published in: Endocrine | Issue 2/2014

Login to get access

Abstract

Subjects with normal glucose regulation (NGR), whose 1-h postload plasma glucose is ≥8.6 mmol/L (155 mg/dL, NGR 1 h ≥ 8.6) during 75-g oral glucose tolerance test (OGTT), have an increased risk of type 2 diabetes and subclinical organ damage. And, the deficiency in islet β cell function is responsible for glycemic disorders. The purpose of this study is to investigate glycemic variability in NGR subjects with elevated 1-h postload plasma glucose levels and its association with islet β cell function. The 29 NGR subjects with 1-h postload plasma glucose ≥8.6 mmol/L (NGR 1 h ≥ 8.6) and 29 age- and sex-matched NGR subjects with 1-h postload plasma glucose <8.6 mmol/L (NGR 1 h < 8.6) were recruited in the study. Insulin sensitivity (Matsuda index, ISI), insulin secretion (insulinogenic index ΔI30/ΔG30), and integrated β cell function measured by the oral disposition index (ΔI30/ΔG30 multiplied by the ISI) were derived from OGTT. All subjects were monitored using the continuous glucose monitoring system for consecutive 72 h. The multiple parameters of glycemic variability included the standard deviation of blood glucose (SDBG), mean blood glucose (MBG), mean of daily differences (MODD), and mean amplitude of glycemic excursions (MAGE). MAGE is considered as a gold standard of glycemic variability. Glycemic variability parameters SDBG, MBG, MODD, and MAGE in NGR 1 h ≥ 8.6 group were higher than those in NGR 1 h < 8.6 group (p < 0.05), and oral disposition index in NGR 1 h ≥ 8.6 group was lower than that in NGR 1 h < 8.6 group (p < 0.05). SDBG, MBG, MODD, MAGE, and 1-h postload plasma glucose all negatively associated with oral disposition index in the separate group (p < 0.05) and in the whole subjects (p < 0.05). After multivariate regression analysis, oral disposition index was the strongest independent contributor to MAGE and 1-h postload plasma glucose in the separate group (p < 0.05) and in the whole subjects (p < 0.05). It is concluded that NGR 1 h ≥ 8.6 group had higher glycemic variability and lower oral disposition index, compared with NGR 1 h < 8.6 group. Increased glycemic variability parameters and elevated 1-h postload plasma glucose consistently associated with declined oral disposition index in subjects from NGR 1 h < 8.6 to NGR 1 h ≥ 8.6 group.
Literature
2.
go back to reference M.A. Abdul-Ghani, T. Abdul-Ghani, N. Ali, R.A. Defronzo, One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care 31, 1650–1655 (2008)PubMedCentralPubMedCrossRef M.A. Abdul-Ghani, T. Abdul-Ghani, N. Ali, R.A. Defronzo, One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care 31, 1650–1655 (2008)PubMedCentralPubMedCrossRef
3.
go back to reference E. Succurro, M.A. Marini, F. Arturi, A. Grembiale, M. Lugarà, F. Andreozzi, A. Sciacqua, R. Lauro, M.L. Hribal, F. Perticone, G. Sesti, Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis. Atherosclerosis 207, 245–249 (2009)PubMedCrossRef E. Succurro, M.A. Marini, F. Arturi, A. Grembiale, M. Lugarà, F. Andreozzi, A. Sciacqua, R. Lauro, M.L. Hribal, F. Perticone, G. Sesti, Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis. Atherosclerosis 207, 245–249 (2009)PubMedCrossRef
4.
go back to reference E. Succurro, F. Arturi, M. Lugarà, A. Grembiale, T.V. Fiorentino, V. Caruso, F. Andreozzi, A. Sciacqua, M.L. Hribal, F. Perticone, G. Sesti, One-hour postload plasma glucose levels are associated with kidney dysfunction. Clin. J. Am. Soc. Nephrol. 5, 1922–1927 (2010)PubMedCentralPubMedCrossRef E. Succurro, F. Arturi, M. Lugarà, A. Grembiale, T.V. Fiorentino, V. Caruso, F. Andreozzi, A. Sciacqua, M.L. Hribal, F. Perticone, G. Sesti, One-hour postload plasma glucose levels are associated with kidney dysfunction. Clin. J. Am. Soc. Nephrol. 5, 1922–1927 (2010)PubMedCentralPubMedCrossRef
5.
go back to reference F. Zaccardi, D. Pitocco, G. Ghirlanda, Glycemic risk factors of diabetic vascular complications: the role of glycemic variability. Diabetes Metab. Res. Rev. 25, 199–207 (2009)PubMedCrossRef F. Zaccardi, D. Pitocco, G. Ghirlanda, Glycemic risk factors of diabetic vascular complications: the role of glycemic variability. Diabetes Metab. Res. Rev. 25, 199–207 (2009)PubMedCrossRef
6.
go back to reference M. Brownlee, I.B. Hirsch, Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 295, 1707–1708 (2006)PubMedCrossRef M. Brownlee, I.B. Hirsch, Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 295, 1707–1708 (2006)PubMedCrossRef
7.
go back to reference D.C. Klonoff, B. Buckingham, J.S. Christiansen, V.M. Montori, W.V. Tamborlane, R.A. Vigersky, H. Wolpert, Endocrine society, continuous glucose monitoring: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 2968–2979 (2011)PubMedCrossRef D.C. Klonoff, B. Buckingham, J.S. Christiansen, V.M. Montori, W.V. Tamborlane, R.A. Vigersky, H. Wolpert, Endocrine society, continuous glucose monitoring: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 2968–2979 (2011)PubMedCrossRef
8.
go back to reference N. Mauras, L. Fox, K. Englert, R.W. Beck, Continuous glucose monitoring in type 1 diabetes. Endocrine 43, 41–50 (2013)PubMedCrossRef N. Mauras, L. Fox, K. Englert, R.W. Beck, Continuous glucose monitoring in type 1 diabetes. Endocrine 43, 41–50 (2013)PubMedCrossRef
9.
go back to reference N.R. Hill, N.S. Oliver, P. Choudhary, J.C. Levy, P. Hindmarsh, D.R. Matthews, Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol. Ther. 13, 921–928 (2011)PubMedCentralPubMedCrossRef N.R. Hill, N.S. Oliver, P. Choudhary, J.C. Levy, P. Hindmarsh, D.R. Matthews, Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol. Ther. 13, 921–928 (2011)PubMedCentralPubMedCrossRef
10.
go back to reference M.A. Abdul-Ghani, K. Williams, R. DeFronzo, M. Stern, Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care 29, 1613–1618 (2006)PubMedCrossRef M.A. Abdul-Ghani, K. Williams, R. DeFronzo, M. Stern, Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care 29, 1613–1618 (2006)PubMedCrossRef
11.
go back to reference M.A. Abdul-Ghani, D. Tripathy, R.A. DeFronzo, Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29, 1130–1139 (2006)PubMedCrossRef M.A. Abdul-Ghani, D. Tripathy, R.A. DeFronzo, Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29, 1130–1139 (2006)PubMedCrossRef
12.
go back to reference A. Festa, K. Williams, A.J. Hanley, S.M. Haffner, Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57, 1638–1644 (2008)PubMedCrossRef A. Festa, K. Williams, A.J. Hanley, S.M. Haffner, Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57, 1638–1644 (2008)PubMedCrossRef
13.
go back to reference M.A. Abdul-Ghani, K. Williams, R.A. DeFronzo, M. Stern, What is the best predictor of future type 2 diabetes? Diabetes Care 30, 1544–1548 (2007)PubMedCrossRef M.A. Abdul-Ghani, K. Williams, R.A. DeFronzo, M. Stern, What is the best predictor of future type 2 diabetes? Diabetes Care 30, 1544–1548 (2007)PubMedCrossRef
14.
go back to reference M. Stumvoll, A. Mitrakou, W. Pimenta, T. Jenssen, H. Yki-Järvinen, T. Van Haeften, W. Renn, J. Gerich, Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23, 295–301 (2000)PubMedCrossRef M. Stumvoll, A. Mitrakou, W. Pimenta, T. Jenssen, H. Yki-Järvinen, T. Van Haeften, W. Renn, J. Gerich, Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23, 295–301 (2000)PubMedCrossRef
15.
go back to reference J.Y. Kim, D.K. Coletta, L.J. Mandarino, G.Q. Shaibi, Glucose response curve and type 2 diabetes risk in Latino adolescents. Diabetes Care 35, 1925–1930 (2012)PubMedCentralPubMedCrossRef J.Y. Kim, D.K. Coletta, L.J. Mandarino, G.Q. Shaibi, Glucose response curve and type 2 diabetes risk in Latino adolescents. Diabetes Care 35, 1925–1930 (2012)PubMedCentralPubMedCrossRef
16.
go back to reference M. Matsuda, R.A. DeFronzo, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462–1470 (1999)PubMedCrossRef M. Matsuda, R.A. DeFronzo, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462–1470 (1999)PubMedCrossRef
17.
go back to reference R. Oka, K. Yagi, M. Sakurai, K. Nakamura, T. Moriuchi, S. Miyamoto, A. Nohara, M.A. Kawashiri, Y. Takeda, M. Yamagishi, Insulin secretion and insulin sensitivity on the oral glucose tolerance test (OGTT) in middle-aged Japanese. Endocr. J. 59, 55–64 (2012)PubMedCrossRef R. Oka, K. Yagi, M. Sakurai, K. Nakamura, T. Moriuchi, S. Miyamoto, A. Nohara, M.A. Kawashiri, Y. Takeda, M. Yamagishi, Insulin secretion and insulin sensitivity on the oral glucose tolerance test (OGTT) in middle-aged Japanese. Endocr. J. 59, 55–64 (2012)PubMedCrossRef
18.
go back to reference J. Zhou, W. Jia, Y. Bao, X. Ma, W. Lu, H. Li, C. Hu, K. Xiang, Glycemic variability and its responses to intensive insulin treatment in newly diagnosed type 2 diabetes. Med. Sci. Monit. 14, CR552–CR558 (2008)PubMed J. Zhou, W. Jia, Y. Bao, X. Ma, W. Lu, H. Li, C. Hu, K. Xiang, Glycemic variability and its responses to intensive insulin treatment in newly diagnosed type 2 diabetes. Med. Sci. Monit. 14, CR552–CR558 (2008)PubMed
19.
go back to reference J. Zhou, H. Li, X. Ran, W. Yang, Q. Li, Y. Peng, Y. Li, X. Gao, X. Luan, W. Wang, W. Jia, Establishment of normal reference ranges for glycemic variability in Chinese subjects using continuous glucose monitoring. Med. Sci. Monit. 17, CR9–CR13 (2011)PubMedCentralPubMed J. Zhou, H. Li, X. Ran, W. Yang, Q. Li, Y. Peng, Y. Li, X. Gao, X. Luan, W. Wang, W. Jia, Establishment of normal reference ranges for glycemic variability in Chinese subjects using continuous glucose monitoring. Med. Sci. Monit. 17, CR9–CR13 (2011)PubMedCentralPubMed
20.
go back to reference L. Monnier, E. Mas, C. Ginet, F. Michel, L. Villon, J.P. Cristol, C. Colette, Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295, 1681–1687 (2006)PubMedCrossRef L. Monnier, E. Mas, C. Ginet, F. Michel, L. Villon, J.P. Cristol, C. Colette, Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295, 1681–1687 (2006)PubMedCrossRef
21.
go back to reference K.M. Utzschneider, R.L. Prigeon, M.V. Faulenbach, J. Tong, D.B. Carr, E.J. Boyko, D.L. Leonetti, M.J. McNeely, W.Y. Fujimoto, S.E. Kahn, Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32, 335–341 (2009)PubMedCentralPubMedCrossRef K.M. Utzschneider, R.L. Prigeon, M.V. Faulenbach, J. Tong, D.B. Carr, E.J. Boyko, D.L. Leonetti, M.J. McNeely, W.Y. Fujimoto, S.E. Kahn, Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32, 335–341 (2009)PubMedCentralPubMedCrossRef
22.
go back to reference R. Retnakaran, S. Shen, A.J. Hanley, V. Vuksan, J.K. Hamilton, B. Zinman, Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring) 16, 1901–1907 (2008)CrossRef R. Retnakaran, S. Shen, A.J. Hanley, V. Vuksan, J.K. Hamilton, B. Zinman, Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring) 16, 1901–1907 (2008)CrossRef
23.
go back to reference L. Monnier, C. Colette, D.R. Owens, Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J. Diabetes Sci. Technol. 2, 1094–1100 (2008)PubMedCentralPubMedCrossRef L. Monnier, C. Colette, D.R. Owens, Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J. Diabetes Sci. Technol. 2, 1094–1100 (2008)PubMedCentralPubMedCrossRef
24.
go back to reference D. Rodbard, New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol. Ther. 11, 551–565 (2009)PubMedCrossRef D. Rodbard, New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol. Ther. 11, 551–565 (2009)PubMedCrossRef
25.
go back to reference F. Moreau, M.A. Weiller, V. Rosner, L. Weiss, M. Hasselmann, M. Pinget, R. Kessler, L. Kessler, Continuous glucose monitoring in cystic fibrosis patients according to the glucose tolerance. Horm. Metab. Res. 40, 502–506 (2008)PubMedCrossRef F. Moreau, M.A. Weiller, V. Rosner, L. Weiss, M. Hasselmann, M. Pinget, R. Kessler, L. Kessler, Continuous glucose monitoring in cystic fibrosis patients according to the glucose tolerance. Horm. Metab. Res. 40, 502–506 (2008)PubMedCrossRef
26.
go back to reference S.V. Madhu, S.K. Muduli, R. Avasthi, Abnormal glycemic profiles by CGMS in obese first-degree relatives of type 2 diabetes mellitus patients. Diabetes Technol. Ther. 15, 461–465 (2013)PubMedCrossRef S.V. Madhu, S.K. Muduli, R. Avasthi, Abnormal glycemic profiles by CGMS in obese first-degree relatives of type 2 diabetes mellitus patients. Diabetes Technol. Ther. 15, 461–465 (2013)PubMedCrossRef
27.
go back to reference R. Borg, J.C. Kuenen, B. Carstensen, H. Zheng, D.M. Nathan, R.J. Heine, J. Nerup, K. Borch-Johnsen, D.R. Witte, ADAG Study Group, Real-life glycaemic profiles in non-diabetic individuals with low fasting glucose and normal HbA1c: the A1C-derived average glucose (ADAG) study. Diabetologia 53, 1608–1611 (2010)PubMedCentralPubMedCrossRef R. Borg, J.C. Kuenen, B. Carstensen, H. Zheng, D.M. Nathan, R.J. Heine, J. Nerup, K. Borch-Johnsen, D.R. Witte, ADAG Study Group, Real-life glycaemic profiles in non-diabetic individuals with low fasting glucose and normal HbA1c: the A1C-derived average glucose (ADAG) study. Diabetologia 53, 1608–1611 (2010)PubMedCentralPubMedCrossRef
28.
go back to reference C. Wang, L. Lv, Y. Yang, D. Chen, G. Liu, L. Chen, Y. Song, L. He, X. Li, H. Tian, W. Jia, X. Ran, Glucose fluctuations in subjects with normal glucose tolerance, impaired glucose regulation and newly diagnosed type 2 diabetes mellitus. Clin. Endocrinol. (Oxf.) 76, 810–815 (2012)CrossRef C. Wang, L. Lv, Y. Yang, D. Chen, G. Liu, L. Chen, Y. Song, L. He, X. Li, H. Tian, W. Jia, X. Ran, Glucose fluctuations in subjects with normal glucose tolerance, impaired glucose regulation and newly diagnosed type 2 diabetes mellitus. Clin. Endocrinol. (Oxf.) 76, 810–815 (2012)CrossRef
29.
go back to reference A. Lapolla, A. Mosca, D. Fedele, The general use of glycated haemoglobin for the diagnosis of diabetes and other categories of glucose intolerance: still a long way to go. Nutr. Metab. Cardiovasc. Dis. 21, 467–475 (2011)PubMedCrossRef A. Lapolla, A. Mosca, D. Fedele, The general use of glycated haemoglobin for the diagnosis of diabetes and other categories of glucose intolerance: still a long way to go. Nutr. Metab. Cardiovasc. Dis. 21, 467–475 (2011)PubMedCrossRef
30.
go back to reference A. Sciacqua, R. Maio, S. Miceli, A. Pascale, G. Carullo, N. Grillo, F. Arturi, G. Sesti, F. Perticone, Association between one-hour post-load plasma glucose levels and vascular stiffness in essential hypertension. PLoS One 7, e44470 (2012)PubMedCentralPubMedCrossRef A. Sciacqua, R. Maio, S. Miceli, A. Pascale, G. Carullo, N. Grillo, F. Arturi, G. Sesti, F. Perticone, Association between one-hour post-load plasma glucose levels and vascular stiffness in essential hypertension. PLoS One 7, e44470 (2012)PubMedCentralPubMedCrossRef
31.
go back to reference A. Sciacqua, S. Miceli, G. Carullo, L. Greco, E. Succurro, F. Arturi, G. Sesti, F. Perticone, One-hour postload plasma glucose levels and left ventricular mass in hypertensive patients. Diabetes Care 34, 1406–1411 (2011)PubMedCentralPubMedCrossRef A. Sciacqua, S. Miceli, G. Carullo, L. Greco, E. Succurro, F. Arturi, G. Sesti, F. Perticone, One-hour postload plasma glucose levels and left ventricular mass in hypertensive patients. Diabetes Care 34, 1406–1411 (2011)PubMedCentralPubMedCrossRef
32.
go back to reference A. Sciacqua, S. Miceli, L. Greco, F. Arturi, P. Naccarato, D. Mazzaferro, E.J. Tassone, L. Turano, F. Martino, G. Sesti, F. Perticone, One-hour postload plasma glucose levels and diastolic function in hypertensive patients. Diabetes Care 34, 2291–2296 (2011)PubMedCentralPubMedCrossRef A. Sciacqua, S. Miceli, L. Greco, F. Arturi, P. Naccarato, D. Mazzaferro, E.J. Tassone, L. Turano, F. Martino, G. Sesti, F. Perticone, One-hour postload plasma glucose levels and diastolic function in hypertensive patients. Diabetes Care 34, 2291–2296 (2011)PubMedCentralPubMedCrossRef
33.
go back to reference N. Taheri, B. Iraj, M. Amini, P. Amini, A. Aminorroaya, Cardiovascular risk factors in relatives of type 2 diabetics with normal glucose tolerance test and elevated one-hour plasma glucose. Endokrynol. Pol. 61, 359–363 (2010)PubMed N. Taheri, B. Iraj, M. Amini, P. Amini, A. Aminorroaya, Cardiovascular risk factors in relatives of type 2 diabetics with normal glucose tolerance test and elevated one-hour plasma glucose. Endokrynol. Pol. 61, 359–363 (2010)PubMed
34.
go back to reference K. Torimoto, Y. Okada, H. Mori, Y. Tanaka, Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc. Diabetol. 12, 1 (2013)PubMedCentralPubMedCrossRef K. Torimoto, Y. Okada, H. Mori, Y. Tanaka, Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc. Diabetol. 12, 1 (2013)PubMedCentralPubMedCrossRef
35.
go back to reference M. Brownlee, Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813–820 (2001)PubMedCrossRef M. Brownlee, Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813–820 (2001)PubMedCrossRef
36.
go back to reference M. Brownlee, The pathophysiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615–1625 (2005)PubMedCrossRef M. Brownlee, The pathophysiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615–1625 (2005)PubMedCrossRef
37.
go back to reference M.A. Marini, E. Succurro, S. Frontoni, S. Mastroianni, F. Arturi, A. Sciacqua, R. Lauro, M.L. Hribal, F. Perticone, G. Sesti, Insulin sensitivity, β-cell function, and incretin effect in individuals with elevated 1-hour postload plasma glucose levels. Diabetes Care 35, 868–872 (2012)PubMedCentralPubMedCrossRef M.A. Marini, E. Succurro, S. Frontoni, S. Mastroianni, F. Arturi, A. Sciacqua, R. Lauro, M.L. Hribal, F. Perticone, G. Sesti, Insulin sensitivity, β-cell function, and incretin effect in individuals with elevated 1-hour postload plasma glucose levels. Diabetes Care 35, 868–872 (2012)PubMedCentralPubMedCrossRef
38.
go back to reference M. Bergman, Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine 43, 504–513 (2013)PubMedCrossRef M. Bergman, Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine 43, 504–513 (2013)PubMedCrossRef
39.
go back to reference R.E. Pratley, C. Weyer, The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 44, 929–945 (2001)PubMedCrossRef R.E. Pratley, C. Weyer, The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 44, 929–945 (2001)PubMedCrossRef
40.
go back to reference M. Fukushima, H. Suzuki, Y. Seino, Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res. Clin. Pract. 66, S37–S43 (2004)PubMedCrossRef M. Fukushima, H. Suzuki, Y. Seino, Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res. Clin. Pract. 66, S37–S43 (2004)PubMedCrossRef
41.
go back to reference S. Del Prato, Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia 46, M2–M8 (2003)PubMed S. Del Prato, Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia 46, M2–M8 (2003)PubMed
42.
go back to reference R.N. Bergman, M. Ader, K. Huecking, G. Van Citters, Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 51, S212–S220 (2002)PubMedCrossRef R.N. Bergman, M. Ader, K. Huecking, G. Van Citters, Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 51, S212–S220 (2002)PubMedCrossRef
43.
go back to reference K.D. Kohnert, P. Augstein, E. Zander, P. Heinke, K. Peterson, E.J. Freyse, R. Hovorka, E. Salzsieder, Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 32, 1058–1062 (2009)PubMedCentralPubMedCrossRef K.D. Kohnert, P. Augstein, E. Zander, P. Heinke, K. Peterson, E.J. Freyse, R. Hovorka, E. Salzsieder, Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 32, 1058–1062 (2009)PubMedCentralPubMedCrossRef
Metadata
Title
Glycemic variability in normal glucose regulation subjects with elevated 1-h postload plasma glucose levels
Authors
Jian-bin Su
Tong Chen
Feng Xu
Xue-qin Wang
Jin-feng Chen
Gang Wu
Yan Jin
Xiao-hua Wang
Publication date
01-06-2014
Publisher
Springer US
Published in
Endocrine / Issue 2/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-013-0047-3

Other articles of this Issue 2/2014

Endocrine 2/2014 Go to the issue

Pros and Cons in Endocrine Practice

Cabergoline treatment in acromegaly: pros

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.